Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Tratamiento con Alopregnanolona: Prometedora Terapia para Retardar la Neurodegeneración en el Alzheimer.

First-in-Class Regenerative Therapeutic for Alzheimer’s Promising

30 de octubre de 2023

La alopregnanolona se muestra prometedora a la hora de retrasar la neurodegeneración en las primeras etapas de la enfermedad de Alzheimer. En un estudio de fase 1b/2a, demostró ser seguro, bien tolerado y aumentó el volumen del hipocampo. La alopregnanolona promueve la neurogénesis, reduce la carga de amiloide y mejora la conectividad cerebral. Los primeros datos clínicos sugieren posibles efectos neuroprotectores y regenerativos. Es inminente un ensayo de fase 2b, REGEN-BRAIN, financiado por el Instituto Nacional sobre el Envejecimiento (NIA por sus siglas en inglés) de los EE.UU. Si bien el medicamento se encuentra en sus primeras etapas, su enfoque innovador entusiasma a los expertos, lo que indica un avance potencial en el tratamiento del Alzheimer.